DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

Information source: Hamamatsu University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia; Negative Symptoms; Cognitive Impairments

Intervention: Pergolide (drug) (Drug)

Phase: Phase 2

Status: Suspended

Sponsored by: Hamamatsu University

Official(s) and/or principal investigator(s):
Norio Mori, Ph.D, Study Chair, Affiliation: Hamamatsu University, School of Medicine, Department of Psychiatry and Neurology

Summary

Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients of schizophrenia is of a heuristic value in guiding research in this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative symptoms and cognitive impairments prevailing in most patients with schizophrenia. This double-blind placebo controlled study will investigate the remedial effect of pergolide on negative symptoms and cognitive impairments in schizophrenia.

Clinical Details

Official title: Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia

Study design: Observational Model: Defined Population, Time Perspective: Cross-Sectional

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: Patients

- Were age 18–50 years, met the DSM-IV criteria for schizophrenia

- Were treated with a stable dose of risperidone, raging 2 to 6mg, for more than 8

weeks

- Had a score ≥15 on negative subscale items in Positive and Negative Syndrome Scale

(PANSS)

- Had a minimum period of symptom stability, defined as no more than 20% change on

consecutive ratings on PANSS for at lease 4 weeks Exclusion Criteria:

- Had a history of medical condition or drug treatment that may have affected cognitive

performance

- Had a history of other psychiatric disorders

Locations and Contacts

Hamamatsu University Hospital, Hamamatsu, Shizuoka 431-3192, Japan
Additional Information

Related publications:

Kimberg DY, D'Esposito M. Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia. 2003;41(8):1020-7.

Müller U, von Cramon DY, Pollmann S. D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci. 1998 Apr 1;18(7):2720-8.

Wang M, Vijayraghavan S, Goldman-Rakic PS. Selective D2 receptor actions on the functional circuitry of working memory. Science. 2004 Feb 6;303(5659):853-6.

Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl). 2004 Jun;174(1):3-16. Epub 2004 Apr 30. Review.

Starting date: March 2003
Last updated: September 13, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017